Clopidogrel Bisulfate Tablet, Film Coated
Product Images NDC 55111-671

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 55111-671). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr.reddy's Laboratories Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton1 (Carton1)

Packaging label for Clopidogrel Tablets USP 300 mg, film-coated tablets for oral use, manufactured by Dr. Reddy's Laboratories Limited. The label indicates a unit-dose pack containing 30 tablets (5 blister cards each with 6 tablets). It includes storage instructions, usage notes, and pharmacist dispensing directions. The label features a barcode and a QR code for the medication guide.*

FDA Label Image

Carton2 (Carton2)

Packaging label for Clopidogrel Tablets USP 300 mg by Dr. Reddy's Laboratories Limited. The label indicates 30 tablets per package (5 blister cards each with 6 tablets). Directions for storage and usage are provided, noting the package is not child-resistant and for institutional use only. The label also includes instructions for tablet removal and consumption.*

FDA Label Image

Container1 (Container1)

Clopidogrel Tablets, USP 300 mg film-coated tablets packaging label by Dr. Reddy's Laboratories Limited. The label indicates 30 tablets per package and is for oral use only. It includes directions for use, a barcode, and mentions that the medication guide should be dispensed with the product.*

FDA Label Image

Container2 (Container2)

Label for Clopidogrel bisulfate tablets, USP 300 mg by Dr.Reddy's Laboratories Limited. The film-coated tablets come in a package of 30. The label includes dosage strength, quantity, directions for pharmacists to dispense medication guide, manufacturer information, and a barcode with space for a QR code.*

FDA Label Image

Figure1 (Figure1)

A horizontal bar chart depicting the effect of co-administered proton pump inhibitors (PPIs) on the active metabolite area under the curve (AUC) with mean values and 90% confidence intervals. The PPIs listed are Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg, showing varying degrees of impact relative to a reference line at 1.0 on the x-axis, ranging approximately from 0.4 to 1.4.*

FDA Label Image

Figure2 (Figure2)

A line graph depicting cumulative event rate percentages over 12 months of follow-up comparing Clopidogrel (+ aspirin) with placebo (+ aspirin). The graph shows two curves, with Clopidogrel consistently having a lower cumulative event rate than placebo. Statistical significance is indicated with a p-value of 0.00009.*

FDA Label Image

Figure3 (Figure3)

A forest plot chart depicting hazard ratios with 95% confidence intervals for various subgroups comparing Clopidogrel bisulfate versus placebo. The subgroups include age, gender, race, elevated cardiac enzymes, diabetes, previous myocardial infarction, previous stroke, use of heparin/LMWH, aspirin dosage, GP IIb/IIIa antagonist use, beta-blocker use, and ACE inhibitor use, with an overall summary at the bottom.*

FDA Label Image

Figure4 (Figure4)

A Kaplan-Meier survival curve comparing the percentage of deaths before first discharge over 28 days between placebo and clopidogrel groups. The y-axis shows the percentage dead before first discharge, and the x-axis shows days since randomization (up to 28 days). The graph notes 1845 deaths (8.1%) in the placebo group versus 1726 deaths (7.5%) in the clopidogrel group, indicating a 7% proportional risk reduction with clopidogrel (p=0.03).*

FDA Label Image

Figure5 (Figure5)

A line graph comparing the percentage of patients with death, reinfarction, or stroke before first discharge over 28 days since randomization between Clopidogrel and placebo groups. The y-axis shows percentage with events, and the x-axis shows days since randomization. The graph indicates a 9% proportional risk reduction for Clopidogrel compared to placebo (p=0.002).*

FDA Label Image

Figure6 (Figure6)

A forest plot illustrating odds ratios with 99% confidence intervals across various subgroups comparing Clopidogrel bisulfate and placebo. Subgroups include gender, age at entry, hours since onset, systolic blood pressure, heart rate, and fibronolytic agent use. Numerical data is shown alongside each subgroup with graphical confidence intervals and overall effect.*

FDA Label Image

Figure7 (Figure7)

A line graph displaying the cumulative event rate (%) of fatal or non-fatal vascular events over 36 months of follow-up for aspirin and clopidogrel treatments. The graph shows two lines indicating the event rate for each treatment with a p-value of 0.045 comparing them.*

FDA Label Image

Figure8 (Figure8)

A forest plot chart comparing hazard ratios with 95% confidence intervals for Clopidogrel versus Aspirin among patients with different qualifying conditions: Stroke, Myocardial Infarction (MI), Peripheral Artery Disease (PAD), and Overall. The horizontal axis represents hazard ratios ranging from 0.6 to 1.3, with markers indicating whether results favor Clopidogrel or Aspirin across these conditions.*

FDA Label Image

Structure (Structure)

Chemical structure of Clopidogrel bisulfate, showing the molecular arrangement including a sulfur-containing bicyclic ring and other functional groups, with an associated sulfuric acid component (H2SO4).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.